Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Neurotherapeutics
Erschienen in: Neurotherapeutics 1/2012

01.01.2012 | Review

Treatment of Neuroterrorism

verfasst von: Katharina M. Busl, Thomas P. Bleck

Erschienen in: Neurotherapeutics | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Bioterrorism is defined as the intentional use of biological, chemical, nuclear, or radiological agents to cause disease, death, or environmental damage. Early recognition of a bioterrorist attack is of utmost importance to minimize casualties and initiate appropriate therapy. The range of agents that could potentially be used as weapons is wide, however, only a few of these agents have all the characteristics making them ideal for that purpose. Many of the chemical and biological weapons can cause neurological symptoms and damage the nervous system in varying degrees. Therefore, preparedness among neurologists is important. The main challenge is to be cognizant of the clinical syndromes and to be able to differentiate diseases caused by bioterrorism from naturally occurring disorders. This review provides an overview of the biological and chemical warfare agents, with a focus on neurological manifestation and an approach to treatment from a perspective of neurological critical care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Greenfield RA, Brown BR, Hutchins JB, et al. Microbiological, biological, and chemical weapons of warfare and terrorism. Am J Med Sci 2002;323:326–340.PubMedCrossRef
2.
Usamriid’s Medical Management of Biological Casualties Handbook. Woods, JB, lead editor. U.S. Army Medical Research, Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland; 2005.
3.
Keim M, Kaufmann AF. Principles for emergency response to bioterrorism. Ann Emerg Med 1999;34:177–182.PubMedCrossRef
4.
Hupert N, Wattson D, Cuomo J, Benson S. Anticipating demand for emergency health services due to medication-related adverse events after rapid mass prophylaxis campaigns. Acad Emerg Med 2007;14:268–274.PubMedCrossRef
5.
6.
Berns KI, Atlas RM, Cassell G, Shoemaker J. Preventing the misuse of microorganisms: the role of the American Society for Microbiology in protecting against biological weapons. Crit Rev Microbiol 1998;24:273–280.PubMedCrossRef
7.
From the Centers for Disease Control and Prevention. Recognition of illness associated with the intentional release of a biologic agent. JAMA 2001;286:2088–2090.CrossRef
8.
Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399–411.PubMedCrossRef
9.
10.
Moran GJ, Talan DA, Abrahamian FM. Biological terrorism. Infect Dis Clin North Am 2008;22:145–187.PubMedCrossRef
11.
Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. MMWR Recomm Rep 2000;49:1–14.
12.
Kman NE, Nelson RN. Infectious agents of bioterrorism: a review for emergency physicians. Emerg Med Clin North Am 2008;26:517–547.PubMedCrossRef
13.
Wallin A, Luksiene Z, Zagminas K, Surkiene G. Public health and bioterrorism: renewed threat of anthrax and smallpox. Medicina (Kaunas) 2007;43:278–284.
14.
Martin CO, Adams HP, Jr. Neurological aspects of biological and chemical terrorism: a review for neurologists. Arch Neurol 2003;60:21–25.PubMedCrossRef
15.
16.
Prockop LD. Weapons of mass destruction: Overview of the CBRNEs (Chemical, Biological, Radiological, Nuclear, and Explosives). J Neurol Sci 2006;249:50–54.PubMedCrossRef
17.
Han MH, Zunt JR. Bioterrorism and the nervous system. Curr Neurol Neurosci Rep 2003;3:476–482.PubMedCrossRef
18.
Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999;281:1735–1745.PubMedCrossRef
19.
Atlas RM. Responding to the threat of bioterrorism: a microbial ecology perspective — the case of anthrax. Int Microbiol 2002;5:161–167.PubMedCrossRef
20.
Whitby M, Ruff TA, Street AC, Fenner FJ. Biological agents as weapons 2: anthrax and plague. Med J Aust 2002;176:605–608.PubMed
21.
Erickson MC, Kornacki JL. Bacillus anthracis: current knowledge in relation to contamination of food. J Food Prot 2003;66:691–699.PubMed
22.
Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239–1243.PubMedCrossRef
23.
Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287:2236–2252.PubMedCrossRef
24.
Bartlett JG, Inglesby TV Jr, Borio L. Management of anthrax. Clin Infect Dis 2002;35:851–858.PubMedCrossRef
25.
26.
27.
Holty JE, Kim RY, Bravata DM. Anthrax: a systematic review of atypical presentations. Ann Emerg Med 2006;48:200–211.PubMedCrossRef
28.
Guillemin J. Anthrax: the investigation of a deadly outbreak. Berkely: University of California Press; 1999.CrossRef
29.
Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001;7:933–944.PubMedCrossRefPubMedCentral
30.
31.
Kim HJ, Jun WB, Lee SH, Rho MH. CT and MR findings of anthrax meningoencephalitis: report of two cases and review of the literature. AJNR Am J Neuroradiol 2001;22:1303–1305.PubMed
32.
Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993;90:2291–2294.PubMedCrossRefPubMedCentral
33.
Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002;418:884–889.PubMedCrossRef
34.
Kyriacou DN, Adamski A, Khardori N. Anthrax: from antiquity and obscurity to a front-runner in bioterrorism. Infect Dis Clin North Am 2006;20:227–251.PubMedCrossRef
35.
Kerrison JB, Lounsbury D, Thirkill CE, Lane RG, Schatz MP, Engler RM. Optic neuritis after anthrax vaccination. Ophthalmology 2002;109:99–104.PubMedCrossRef
36.
37.
38.
39.
Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis 2005;40:1166–1172.PubMedCrossRef
40.
41.
Gage KL, Dennis DT, Orloski KA, et al. Cases of cat-associated human plague in the Western US, 1977–1998. Clin Infect Dis 2000;30:893–900.PubMedCrossRef
42.
Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000;283:2281–2290.PubMedCrossRef
43.
Becker TM, Poland JD, Quan TJ, White ME, Mann JM, Barnes AM. Plague meningitis — a retrospective analysis of cases reported in the United States, 1970–1979. West J Med 1987;147:554–557.PubMedPubMedCentral
44.
45.
46.
47.
Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 1985;64:251–269.
48.
Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285:2763–2773.PubMedCrossRef
49.
Koskela P, Salminen A. Humoral immunity against Francisella tularensis after natural infection. J Clin Microbiol 1985;22:973–979.PubMedPubMedCentral
50.
Bevanger L, Maeland JA, Naess AI. Agglutinins and antibodies to Francisella tularensis outer membrane antigens in the early diagnosis of disease during an outbreak of tularemia. J Clin Microbiol 1988;26:433–437.PubMedPubMedCentral
51.
Eliasson H, Sjostedt A, Back E. Clinical use of a diagnostic PCR for Francisella tularensis in patients with suspected ulceroglandular tularaemia. Scand J Infect Dis 2005;37:833–837.PubMedCrossRef
52.
Rosenbloom M, Leikin JB, Vogel SN, Chaudry ZA. Biological and chemical agents: a brief synopsis. Am J Ther 2002;9:5–14.PubMedCrossRef
53.
Dupuis G, Petite J, Peter O, Vouilloz M. An important outbreak of human Q fever in a Swiss Alpine valley. Int J Epidemiol 1987;16:282–287.PubMedCrossRef
54.
Tissot Dupont H, Raoult D, Brouqui P, et al. Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases. Am J Med 1992;93:427–434.
55.
Gilbert DN, Moellering, RC, Eliopoulis GM, Saag MS, Chambers HF. The Sanford Guide to Antimicrobial therapy. 41st ed. Sperryvillie, VA: Antimicrobial Therapy, Inc.; 2011.
56.
Buchanan TM, Hendricks SL, Patton CM, Feldman RA. Brucellosis in the United States, 1960–1972; An abattoir-associated disease. Part III. Epidemiology and evidence for acquired immunity. Medicine (Baltimore) 1974;53:427–439.CrossRef
57.
Mousa AR, Elhag KM, Khogali M, Marafie AA. The nature of human brucellosis in Kuwait: study of 379 cases. Rev Infect Dis 1988;10:211–217.PubMedCrossRef
58.
59.
Shakir RA, Al-Din AS, Araj GF, Lulu AR, Mousa AR, Saadah MA. Clinical categories of neurobrucellosis. A report on 19 cases. Brain 1987;110:213–223.
60.
McLean DR, Russell N, Khan MY. Neurobrucellosis: clinical and therapeutic features. Clin Infect Dis 1992;15:582–590.PubMedCrossRef
61.
Laboratory-acquired human glanders — Maryland, May 2000. MMWR Morb Mortal Wkly Rep 2000;49:532–535.
62.
63.
64.
Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287:2391–2405.PubMedCrossRef
65.
Bossi P, Garin D, Guihot A, et al. Bioterrorism: management of major biological agents. Cell Mol Life Sci 2006;63:2196–2212.PubMedCrossRef
66.
Cleri DJ, Villota FJ, Porwancher RB. Smallpox, bioterrorism, and the neurologist. Arch Neurol 2003;60:489–494.PubMedCrossRef
67.
Bartlett J, Borio L, Radonovich L, et al. Smallpox vaccination in 2003: key information for clinicians. Clin Infect Dis 2003;36:883–902.PubMedCrossRef
68.
Alibek K. HS. Biohazard. New York: Delta, 2000.
69.
Update: adverse events following civilian smallpox vaccination — United States, 2003. MMWR Morb Mortal Wkly Rep 2004;53:106–107.
70.
71.
Cleri DJ, Ricketti AJ, Porwancher RB, Ramos-Bonner LS, Vernaleo JR. Viral hemorrhagic fevers: current status of endemic disease and strategies for control. Infect Dis Clin North Am 2006;20:359–393.PubMedCrossRef
72.
Petersen L, Gubler D. Alphaviruses, in Warrell, D., Cox, T., Firth, J., Benz, E.: Oxford Textbook of Medicine, 5th edition, Oxford university press 2010.
73.
Deresiewicz RL, Thaler SJ, Hsu L, Zamani AA. Clinical and neuroradiographic manifestations of eastern equine encephalitis. N Engl J Med 1997;336:1867–1874.PubMedCrossRef
74.
Johnson KM, Martin DH. Venezuelan equine encephalitis. Adv Vet Sci Comp Med 1974;18:79–116.PubMed
75.
Bronze MS, Huycke MM, Machado LJ, Voskuhl GW, Greenfield RA. Viral agents as biological weapons and agents of bioterrorism. Am J Med Sci 2002;323:316–325.PubMedCrossRef
76.
Lukaszewski RA, Brooks TJ. Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J Virol 2000;74:5006–5015.PubMedCrossRefPubMedCentral
77.
Paredes A, Alwell-Warda K, Weaver SC, Chiu W, Watowich SJ. Structure of isolated nucleocapsids from venezuelan equine encephalitis virus and implications for assembly and disassembly of enveloped virus. J Virol 2003;77:659–664.PubMedCrossRefPubMedCentral
78.
Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059–1070.PubMedCrossRef
79.
Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998;129:221–228.PubMedCrossRef
80.
Woodruff BA, Griffin PM, McCroskey LM, et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975–1988. J Infect Dis 1992;166:1281–1286.PubMedCrossRef
81.
82.
Bleck TP. Clostridium Botulinum (botulism). In: Mandell GL, Bennett, J.E., Dolin, R., editor. Principles and Practice of Infectious Diseases. 7th edition ed. Philadelphia: Churchill Livingstone; 2009. p. 3097-102.
83.
Blazes DL, Lawler JV, Lazarus AA. When biotoxins are tools of terror. Early recognition of intentional poisoning can attenuate effects. Postgrad Med 2002;112:89–98.PubMed
84.
Zouari N, Choyakh F, Triki C, Mhiri C. [Importance of electromyography in the diagnosis of botulism]. Neurophysiol Clin 1997;27:220–226.PubMedCrossRef
85.
Maselli RA, Bakshi N. AAEM case report 16. Botulism. American Association of Electrodiagnostic Medicine. Muscle Nerve 2000;23:1137–1144.PubMedCrossRef
86.
Chen JT, Chen CC, Lin KP, Wang SJ, Wu ZA, Liao KK. Botulism: heart rate variation, sympathetic skin responses, and plasma norepinephrine. Can J Neurol Sci 1999;26:123–126.PubMed
87.
Hibbs RG, Weber JT, Corwin A, et al. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 1996;23:337–340.PubMedCrossRef
88.
Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984;76:794–798.PubMedCrossRef
89.
Services USPH. Botulism in the United States, 1899–1973: Handbook for Epidemiologists, Clinicians and Laboratory Workers. Atlanta: US Dept. of Health, Education and Welfare, 1974.
90.
91.
Henghold WB, 2nd. Other biologic toxin bioweapons: ricin, staphylococcal enterotoxin B, and trichothecene mycotoxins. Dermatol Clin 2004;22:257–262.PubMedCrossRef
92.
93.
Kortepeter MCG, Cieslak T, et al. USAM-RIID's medical management of biological casualties handbook. Fort Detrick, Maryland: US Army Medical Research Institute of Infectious Diseases, 2001.
94.
Barg NL. The staphylococci in human disease, Crossley, KB, Archer, GL (Eds), Churchill Livingstone, New York, 1997.
95.
Holmberg SD, Blake PA. Staphylococcal food poisoning in the United States. New facts and old misconceptions. JAMA. 1984 Jan 27;251(4):487–9.PubMedCrossRef
96.
Lehane L. Paralytic shellfish poisoning: a potential public health problem. Med J Aust 2001;175:29–31.PubMed
97.
Kiernan MC, Isbister GK, Lin CS, Burke D, Bostock H. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol 2005;57:339–348.PubMedCrossRef
98.
Chew SK, Chew LS, Wang KW, Mah PK, Tan BY. Anticholinesterase drugs in the treatment of tetrodotoxin poisoning. Lancet 1984;2:108.PubMedCrossRef
99.
100.
Augerson WS. Nerve Agents. Washington DC: RAND Corporation. 2000.
101.
Namba T, Nolte CT, Jackrel J, Grob D. Poisoning due to organophosphate insecticides. Acute and chronic manifestations. Am J Med 1971;50:475–492.PubMedCrossRef
102.
Gunderson CH, Lehmann CR, Sidell FR, Jabbari B. Nerve agents: a review. Neurology 1992;42:946–950.PubMedCrossRef
103.
Suzuki T, Morita H, Ono K, Maekawa K, Nagai R, Yazaki Y. Sarin poisoning in Tokyo subway. Lancet 1995;345:980.PubMedCrossRef
104.
Wadia RS, Chitra S, Amin RB, Kiwalkar RS, Sardesai HV. Electrophysiological studies in acute organophosphate poisoning. J Neurol Neurosurg Psychiatry 1987;50:1442–1448.PubMedCrossRefPubMedCentral
105.
Besser R, Gutmann L, Dillmann U, Weilemann LS, Hopf HC. End-plate dysfunction in acute organophosphate intoxication. Neurology 1989;39:561–567.PubMedCrossRef
106.
Dunn MA, Sidell FR. Progress in medical defense against nerve agents. JAMA 1989;262:649–652.PubMedCrossRef
107.
Singh S, Chaudhry D, Behera D, Gupta D, Jindal SK. Aggressive atropinisation and continuous pralidoxime (2-PAM) infusion in patients with severe organophosphate poisoning: experience of a northwest Indian hospital. Hum Exp Toxicol 2001;20:15–18.PubMedCrossRef
108.
Dorandeu F, Carpentier P, Baubichon D, et al. Efficacy of the ketamine-atropine combination in the delayed treatment of soman-induced status epilepticus. Brain Res 2005;1051:164–175.PubMedCrossRef
109.
Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med 1987;316:761–763.PubMedCrossRef
110.
Senanayake N, Johnson MK. Acute polyneuropathy after poisoning by a new organophosphate insecticide. N Engl J Med 1982;306:155–157.PubMedCrossRef
111.
Lotti M, Becker CE, Aminoff MJ. Organophosphate polyneuropathy: pathogenesis and prevention. Neurology 1984;34:658–662.PubMedCrossRef
112.
De Bleecker JL, De Reuck JL, Willems JL. Neurological aspects of organophosphate poisoning. Clin Neurol Neurosurg 1992;94:93–103.PubMedCrossRef
113.
Kadar T, Shapira S, Cohen G, Sahar R, Alkalay D, Raveh L. Sarin-induced neuropathology in rats. Hum Exp Toxicol 1995;14:252–259.PubMedCrossRef
114.
Barkman WH. Respiratory tract irritants. Environmental and occupational medicine. [Bookchapter]. Rom WN, ed. Boston: Little Brown 1992: 529–533.
115.
Smith KJ, Hurst CG, Moeller RB, Skelton HG, Sidell FR. Sulfur mustard: its continuing threat as a chemical warfare agent, the cutaneous lesions induced, progress in understanding its mechanism of action, its long-term health effects, and new developments for protection and therapy. J Am Acad Dermatol 1995;32(5 pt 1):765–776.PubMedCrossRef
116.
Borak J, Sidell FR. Agents of chemical warfare: sulfur mustard. Ann Emerg Med 1992;21:303–308.PubMedCrossRef
117.
Dacre JC, Goldman M. Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Pharmacol Rev 1996;48:289–326.PubMed
118.
Watson AP, Griffin GD. Toxicity of vesicant agents scheduled for destruction by the Chemical Stockpile Disposal Program. Environ Health Perspect 1992;98:259–280.PubMedCrossRefPubMedCentral
119.
120.
Yen D, Tsai J, Wang LM, et al. The clinical experience of acute cyanide poisoning. Am J Emerg Med 1995;13:524–528.PubMedCrossRef
121.
Sauer SW, Keim ME. Hydroxocobalamin: improved public health readiness for cyanide disasters. Ann Emerg Med 2001;37:635–641.PubMedCrossRef
122.
Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RS, Howland MA, Hoffman RS. Goldfrank's toxicologic emergencies, 5th ed. Norwalk, Connecticut: Appleton & Lange, 1994.
123.
Metadaten
Titel
Treatment of Neuroterrorism
verfasst von
Katharina M. Busl
Thomas P. Bleck
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Neurotherapeutics / Ausgabe 1/2012
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-011-0097-2

Weitere Artikel der Ausgabe 1/2012

Neurotherapeutics 1/2012 Zur Ausgabe

PROGRAM

Fifth Annual Huntington Disease Clinical Research Symposium

Review

The Utility of EEG, SSEP, and Other Neurophysiologic Tools to Guide Neurocritical Care

Original Article

Glucocorticoid-Induced Leucine Zipper (GILZ) Over-Expression in T Lymphocytes Inhibits Inflammation and Tissue Damage in Spinal Cord Injury

Review

Neuro-Intensive Care of Patients with Acute CNS Infections

Review

Therapeutic Strategies in Acute Intracerebral Hemorrhage

Original Article

C3 Peptide Promotes Axonal Regeneration and Functional Motor Recovery after Peripheral Nerve Injury

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

03.05.2024 Parkinson-Krankheit Nachrichten

Kann eine frühzeitige Stuhltransplantation das Fortschreiten von Parkinson-Symptomen verlangsamen? Die Ergebnisse einer randomisierten Phase-2-Studie scheinen dafür zu sprechen.

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

02.05.2024 Hirnblutung Nachrichten

Erhalten Personen mit einer spontanen Hirnblutung innerhalb von zwei Stunden nach Symptombeginn eine Tranexamsäure-Therapie, kann dies weder die Hämatomexpansion eindämmen noch die Mortalität senken.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise